West Pharmaceutical Services (WST)
(Delayed Data from NYSE)
$314.77 USD
-1.73 (-0.55%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $315.11 +0.34 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$314.77 USD
-1.73 (-0.55%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $315.11 +0.34 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Zacks News
Bruker's (BRKR) Q3 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Bruker's (BRKR) third-quarter 2020 results reflect dismal performances by two of the reporting segments and geographies due to coronavirus-led business disruptions.
Chemed's (CHE) Shares Up on Q3 Earnings and Revenue Beat
by Zacks Equity Research
Chemed (CHE) reports solid revenue growth across key subsidiaries in third-quarter results.
STERIS' (STE) Earnings & Revenues Surpass Estimates in Q2
by Zacks Equity Research
STERIS' (STE) second-quarter fiscal 2021 results reflect strong performance by the Life Sciences and the Applied Sterilization Technologies segments despite the coronavirus-led economic crisis.
Teleflex (TFX) Q3 Earnings & Revenues Beat, Decline Y/Y
by Zacks Equity Research
Teleflex (TFX) witnesses significant sequential improvement in segmental performance on gradual recovery of the economy.
Syneos Health (SYNH) Q3 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Syneos Health (SYNH) registers sales decline in both its business segments due to slower recovery in reimbursable out-of-pocket expenses across both segments.
Illumina (ILMN) Q3 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Illumina (ILMN) exhibits dismal segmental performance in the third quarter of 2020 due to pandemic-led business disruptions.
NuVasive (NUVA) Q3 Earnings Beat, Gross Margin Declines
by Zacks Equity Research
NuVasive (NUVA) registers strong international performance in Q3 along with several spinal hardware product lines growing at high single digits or more.
ResMed (RMD) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
ResMed's (RMD) overall increase in Q1 revenues is driven by robust performance of its mask and device product portfolios on increased demand for ventilators and ventilator masks.
Exact Sciences (EXAS) Loses 5.6% Despite Beating Q3 Earnings
by Zacks Equity Research
Exact Sciences' (EXAS) legacy screening business sees a decline in revenues in Q3 earnings.
Henry Schein (HSIC) Q3 Earnings Top Estimates, Margins Dip
by Zacks Equity Research
Henry Schein (HSIC) sees robust segmental performance in Q3 boosted by strong rebound in sales and solid demand for PPE and COVID-19-related products.
Amedisys (AMED) Beats Q3 Earnings Estimates, Ups 2020 View
by Zacks Equity Research
An impressive Q3 performance by Amedisys' (AMED) Home health and hospice amid the pandemic-led business disruptions buoys optimism.
Bio-Rad (BIO) Q3 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Bio-Rad's (BIO) third-quarter 2020 results reflect strong performance by the Life Science segment, boosted by coronavirus-led increased testing demand.
ABC vs. WST: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ABC vs. WST: Which Stock Is the Better Value Option?
Integra (IART) Q3 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Integra's (IART) third-quarter 2020 results reflect mixed segmental performance with strong recovery trends due to coronavirus-led business disruptions.
IDEXX (IDXX) Earnings Beat Estimates in Q3, Margins Rise
by Zacks Equity Research
IDEXX (IDXX) registered strong contribution from its CAG business in the third quarter despite pandemic-induced challenges.
3 Dental Supplies Stocks Set to Shine on the Industry's Upturn
by Trina Mukherjee
Despite the challenges thrown by the COVID-19 pandemic, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. CAH, WST and MCK are well positioned to gain from the prospects.
QIAGEN (QGEN) Q3 Earnings Beat Estimates, FY20 Guidance Up
by Zacks Equity Research
QIAGEN (QGEN) registeres robust revenue growth across geographies and both operating segments in Q3 despite the coronavirus-led economic crisis.
Boston Scientific (BSX) Q3 Earnings Top, Margins Decline
by Zacks Equity Research
Boston Scientific's (BSX) Q3 earnings and revenues decline year over year but improve sequentially.
Is West Pharmaceutical Services (WST) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (WST) Outperforming Other Medical Stocks This Year?
West Pharmaceutical Services (WST) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 13.86% and 7.20%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
West Pharmaceutical Services (WST) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MCK or WST: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MCK vs. WST: Which Stock Is the Better Value Option?
Here's Why You Should Avoid Betting on Intuitive Surgical Now
by Zacks Equity Research
Intense competition in the global MedTech space and weak operational performance weighs on Intuitive Surgical (ISRG).
Veeva's Offering Chosen by Idorsia to Drive Digital Engagement
by Zacks Equity Research
Veeva Systems' (VEEV) Commercial Cloud selected by Idorsia to enhance its digital field force in the United States, Japan and countries across Europe.
Top Ranked Growth Stocks to Buy for September 22nd
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, September 22nd.